Prosecution Insights
Last updated: October 04, 2026

Inmed Pharmaceuticals Inc.

Technology area: Biotechnology & Pharmaceuticals

3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Analysis

Inmed Pharmaceuticals Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 2 distinct examiners and 2 distinct art units. This distribution shows that the company is engaging with multiple points of review within the patent office simultaneously.

REILLY, SOPHIA JANE is the busiest examiner for the portfolio, with 1 pending office action. The presence of 2 distinct art units suggests that the company's intellectual property spans different specialized sub-sectors of biotechnology.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

3
Total Pending OAs
1
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (67%)
1
Medium (33%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (33%)
§103 only1 (33%)
Multi-statute (no §101)1 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MOU, LIYUAN 1 42.9% +59.0%
REILLY, SOPHIA JANE 1 60.8% +49.2%
REGA, KYLE THOMAS 1 62.7% +41.4%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18033187 COMPOSITIONS AND METHODS FOR TREATING NEURONAL DISORDERS WITH CANNABINOIDS MOU, LIYUAN 45d overdue
17606003 COMPOSITIONS AND METHODS FOR USE OF CANNABINOIDS FOR NEUROPROTECTION REILLY, SOPHIA JANE —

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18033187 COMPOSITIONS AND METHODS FOR TREATING NEURONAL DISORDERS WITH CANNABINOIDS MOU, LIYUAN 45d overdue
17606003 COMPOSITIONS AND METHODS FOR USE OF CANNABINOIDS FOR NEUROPROTECTION REILLY, SOPHIA JANE —
17436548 COMPOSITIONS AND METHODS FOR BIOSYNTHESIS OF TERPENOIDS OR CANNABINOIDS IN A HETEROLOGOUS SYSTEM REGA, KYLE THOMAS —

Top Art Units

Art UnitApps
1628 1
1627 1
1636 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18033187 COMPOSITIONS AND METHODS FOR TREATING NEURONAL DISORDERS WITH CANNABINOIDS MOU, LIYUAN 1628 §102§103§112 Final Rejection 45d overdue Pending Apr 21, 2023
17606003 COMPOSITIONS AND METHODS FOR USE OF CANNABINOIDS FOR NEUROPROTECTION REILLY, SOPHIA JANE 1627 §101§102§103§112Other Non-Final OA — Pending Oct 22, 2021
17436548 COMPOSITIONS AND METHODS FOR BIOSYNTHESIS OF TERPENOIDS OR CANNABINOIDS IN A HETEROLOGOUS SYSTEM REGA, KYLE THOMAS 1636 §103 Final Rejection — Pending Sep 03, 2021

Managing Inmed Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month